SCYNEXIS Management

Management Kriterienprüfungen 2/4

SCYNEXIS CEO ist David Angulo , ernannt in Jan 2023, hat eine Amtszeit von 1.83 Jahren. Die jährliche Gesamtvergütung beträgt $1.21M , bestehend aus 46.5% Gehalt und 53.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.38% der Aktien des Unternehmens, im Wert von €170.37K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.1 Jahre bzw. 9.5 Jahre.

Wichtige Informationen

David Angulo

Geschäftsführender

US$1.2m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	46.5%
Amtszeit als Geschäftsführer	1.8yrs
Eigentum des Geschäftsführers	0.4%
Durchschnittliche Amtszeit des Managements	2.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	9.5yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von David Angulo im Vergleich zu den Einnahmen von SCYNEXIS verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-US$36m
Jun 30 2024	n/a	n/a	-US$35m
Mar 31 2024	n/a	n/a	US$101m
Dec 31 2023	US$1m	US$565k	US$67m
Sep 30 2023	n/a	n/a	US$72m
Jun 30 2023	n/a	n/a	US$44m
Mar 31 2023	n/a	n/a	-US$91m
Dec 31 2022	US$1m	US$482k	-US$63m
Sep 30 2022	n/a	n/a	-US$78m
Jun 30 2022	n/a	n/a	-US$49m
Mar 31 2022	n/a	n/a	-US$34m
Dec 31 2021	US$987k	US$461k	-US$33m
Sep 30 2021	n/a	n/a	-US$46m
Jun 30 2021	n/a	n/a	-US$45m
Mar 31 2021	n/a	n/a	-US$53m
Dec 31 2020	US$939k	US$447k	-US$55m
Sep 30 2020	n/a	n/a	-US$27m
Jun 30 2020	n/a	n/a	-US$36m
Mar 31 2020	n/a	n/a	-US$38m
Dec 31 2019	US$1m	US$437k	-US$54m
Sep 30 2019	n/a	n/a	-US$37m
Jun 30 2019	n/a	n/a	-US$29m
Mar 31 2019	n/a	n/a	-US$31m
Dec 31 2018	US$769k	US$424k	-US$12m
Sep 30 2018	n/a	n/a	-US$22m
Jun 30 2018	n/a	n/a	-US$31m
Mar 31 2018	n/a	n/a	-US$24m
Dec 31 2017	US$768k	US$412k	-US$25m

Vergütung im Vergleich zum Markt: DavidDie Gesamtvergütung ($USD1.21M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt German ($USD474.54K).

Entschädigung vs. Einkommen: DavidDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

David Angulo (59 yo)

1.8yrs

Amtszeit

US$1,214,710

Vergütung

Dr. David Gonzalez Angulo, M. D., had been the Chief Medical Officer at SCYNEXIS, Inc. since June 1, 2015. He is President, Director and Chief Executive Officer of SCYNEXIS, Inc. from January 1, 2023. Dr....

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
David Angulo	CEO, President & Director	1.8yrs	US$1.21m	0.38% € 170.4k
Ivor Macleod	Chief Financial Officer	2.1yrs	US$626.90k	0.028% € 12.4k
Scott Sukenick	Chief Legal Officer & Corporate Secretary	7yrs	US$936.70k	0.21% € 94.5k
Daniella Gigante	Vice President of Human Resources & Information Technology	no data	keine Daten	keine Daten

2.1yrs

Durchschnittliche Betriebszugehörigkeit

59yo

Durchschnittliches Alter

Erfahrenes Management: 135ADas Führungsteam des Unternehmens gilt als erfahren (2.1 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
David Angulo	CEO, President & Director	1.8yrs	US$1.21m	0.38% € 170.4k
Armando Anido	Independent Director	5.8yrs	US$98.75k	0.066% € 29.6k
David Hastings	Independent Director	9.2yrs	US$104.25k	0.061% € 27.4k
Ann Hanham	Independent Director	15.9yrs	US$105.25k	0.062% € 28.0k
Guy MacDonald	Independent Chairman of the Board	10yrs	US$128.75k	0.084% € 37.9k
Steven Gilman	Independent Director	9.8yrs	US$106.25k	0.063% € 28.4k
David Denning	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Peter Pappas	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Oliver Cornely	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Barbara Alexander	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Mahmoud Ghannoum	Member of Scientific Advisory Board	no data	keine Daten	keine Daten
Paul Nyirjesy	Member of Scientific Advisory Board	no data	keine Daten	keine Daten

9.5yrs

Durchschnittliche Betriebszugehörigkeit

65.5yo

Durchschnittliches Alter

Erfahrener Vorstand: 135ADie Vorstandsmitglieder gelten als erfahren (9.5 Jahre durchschnittliche Amtszeit).

SCYNEXIS Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

SCYNEXIS, Inc., Annual General Meeting, Jun 19, 2024

Insufficient new directors

SCYNEXIS, Inc. Announces CEO Changes

SCYNEXIS, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Insufficient new directors

Recent updates

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. to Report Q3, 2024 Results on Oct 18, 2024

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$2.56 profit in 2Q 2023)

First quarter 2024 earnings released: EPS: US$0.009 (vs US$0.71 loss in 1Q 2023)

New major risk - Revenue and earnings growth

SCYNEXIS, Inc., Annual General Meeting, Jun 19, 2024

SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases

Full year 2023 earnings released: EPS: US$1.40 (vs US$1.47 loss in FY 2022)

Bronstein, Gewirtz & Grossman LLC Announces SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.62 loss in 3Q 2022)

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

SCYNEXIS, Inc. Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology

SCYNEXIS, Inc. Issues A Voluntary Nationwide Recall of BREXAFEMME® (Ibrexafungerp Tablets) Due to Potential for Cross Contamination with A Non-Antibacterial ß-Lactam Drug Substance

Investor sentiment improves as stock rises 17%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: US$2.56 (vs US$0.31 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.71 loss per share (vs US$0.17 loss in 1Q 2022)

Forecast breakeven date moved forward to 2023

Forecast to breakeven in 2025

Scynexis AnnouncesFDA Approval of Second Indication for Brexafemme® (Ibrexafungerp Tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

Insufficient new directors

Third quarter 2022 earnings released: US$0.62 loss per share (vs US$0.023 loss in 3Q 2021)

SCYNEXIS, Inc. Announces Positive Results from Pooled Analysis of Two Phase 3 Studies (VANISH-303 and VANISH-306) in the Journal of Women’s Health

SCYNEXIS, Inc. to Report Q3, 2022 Results on Nov 09, 2022

SCYNEXIS, Inc. Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022

SCYNEXIS, Inc. Announces CEO Changes

SCYNEXIS, Inc. Presents Positive Interim Data of ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.064 profit in 2Q 2021)

SCYNEXIS, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting

SCYNEXIS, Inc. Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME

Scynexis Presents Positive Data from Phase 3 Candle Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the Issvd Xxvi World Congress and International Vulvovaginal Disease Update

Scynexis Announces Initiation of New Phase 3B Study (Vanquish) to Evaluate Oral Ibrexafungerp as A Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole

SCYNEXIS, Inc. Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections

SCYNEXIS, Inc., Annual General Meeting, Jun 16, 2022

SCYNEXIS, Inc. Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

SCYNEXIS, Inc. to Report Q1, 2022 Results on May 12, 2022

No longer forecast to breakeven

Insufficient new directors

SCYNEXIS, Inc. has completed a Follow-on Equity Offering in the amount of $44.988333 million.

SCYNEXIS, Inc. Announces Positive Interim Data from its Ongoing Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections

No longer forecast to breakeven

SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections

Insufficient new directors

Forecast to breakeven in 2024

SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis

Scynexis, Inc. Announces Peer-Reviewed Publication of Results

Scynexis, Inc. Announces U.S. Availability of BREXAFEMME®

Scynexis, Inc. Announces Hansoh Pharma’S Application to National Medical Products Administration (Nmpa) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (Vvc)

SCYNEXIS, Inc. Announces Three Oral Presentations of Ibrexafungerp Demonstrating Clinical and in Vitro Activity Against Candida Species At the 31st ECCMID

SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)

SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections

SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections

Forecast breakeven pushed back to 2024

SCYNEXIS, Inc. Provides an Update on Recent Clinical and Corporate Developments

SCYNEXIS, Inc. announced that it expects to receive funding from Hercules Capital, Inc.

Scynexis Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (Furi and Cares)

SCYNEXIS and Amplity Health Announce Agreement to Support the Anticipated U.S. Commercialization of Brexafemme (Ibrexafungerp) for Vaginal Yeast Infections

SCYNEXIS, Inc. Enter into an Exclusive License and Collaboration Agreement with Hansoh (Shanghai) Health Technology Co., Ltd., and Jiangsu Hansoh Pharmaceutical Group Company Limited

New 90-day high: €7.00

New 90-day high: €6.50

CEO, President & Director recently bought €205k worth of stock

SCYNEXIS, Inc. has completed a Follow-on Equity Offering in the amount of $84.99474 million.

New 90-day high: €6.45

SCYNEXIS, Inc. Announces Significant Progress on the Ibrexafungerp IV Formulation and Provided an Update on Its Ongoing Phase 3 Studies in the Hospital Setting

New 90-day high: €5.75

Revenue in line with expectations